These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29914022)

  • 1. Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.
    Salloway SP; Sperling R; Fox NC; Sabbagh MN; Honig LS; Porsteinsson AP; Rofael H; Ketter N; Wang D; Liu E; Carr S; Black RS; Brashear HR
    J Alzheimers Dis; 2018; 64(3):689-707. PubMed ID: 29914022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study.
    Salloway S; Marshall GA; Lu M; Brashear HR
    Curr Alzheimer Res; 2018; 15(13):1231-1243. PubMed ID: 30129411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
    Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
    J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.
    Ivanoiu A; Pariente J; Booth K; Lobello K; Luscan G; Hua L; Lucas P; Styren S; Yang L; Li D; Black RS; Brashear HR; McRae T
    Alzheimers Res Ther; 2016 Jun; 8(1):24. PubMed ID: 27334799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
    Salloway S; Sperling R; Fox NC; Blennow K; Klunk W; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Ferris S; Reichert M; Ketter N; Nejadnik B; Guenzler V; Miloslavsky M; Wang D; Lu Y; Lull J; Tudor IC; Liu E; Grundman M; Yuen E; Black R; Brashear HR;
    N Engl J Med; 2014 Jan; 370(4):322-33. PubMed ID: 24450891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
    Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
    Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
    Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
    Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies.
    Brashear HR; Ketter N; Bogert J; Di J; Salloway SP; Sperling R
    J Alzheimers Dis; 2018; 66(4):1409-1424. PubMed ID: 30412493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.
    Russu A; Samtani MN; Xu S; Adedokun OJ; Lu M; Ito K; Corrigan B; Raje S; Liu E; Brashear HR; Styren S; Hu C
    J Alzheimers Dis; 2016 May; 53(2):535-46. PubMed ID: 27163805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
    Sperling R; Salloway S; Brooks DJ; Tampieri D; Barakos J; Fox NC; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Lieberburg I; Arrighi HM; Morris KA; Lu Y; Liu E; Gregg KM; Brashear HR; Kinney GG; Black R; Grundman M
    Lancet Neurol; 2012 Mar; 11(3):241-9. PubMed ID: 22305802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
    Brody M; Liu E; Di J; Lu M; Margolin RA; Werth JL; Booth K; Shadman A; Brashear HR; Novak G
    J Alzheimers Dis; 2016 Oct; 54(4):1509-1519. PubMed ID: 27589523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
    Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
    Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
    Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.
    Novak G; Fox N; Clegg S; Nielsen C; Einstein S; Lu Y; Tudor IC; Gregg K; Di J; Collins P; Wyman BT; Yuen E; Grundman M; Brashear HR; Liu E
    J Alzheimers Dis; 2016; 49(4):1123-34. PubMed ID: 26639957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
    Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M
    Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks.
    Guthrie H; Honig LS; Lin H; Sink KM; Blondeau K; Quartino A; Dolton M; Carrasco-Triguero M; Lian Q; Bittner T; Clayton D; Smith J; Ostrowitzki S
    J Alzheimers Dis; 2020; 76(3):967-979. PubMed ID: 32568196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer's disease.
    Arai H; Umemura K; Ichimiya Y; Iseki E; Eto K; Miyakawa K; Kirino E; Shibata N; Baba H; Tsuchiwata S
    Geriatr Gerontol Int; 2016 May; 16(5):644-50. PubMed ID: 26044070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
    Salloway S; Sperling R; Gilman S; Fox NC; Blennow K; Raskind M; Sabbagh M; Honig LS; Doody R; van Dyck CH; Mulnard R; Barakos J; Gregg KM; Liu E; Lieberburg I; Schenk D; Black R; Grundman M;
    Neurology; 2009 Dec; 73(24):2061-70. PubMed ID: 19923550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
    Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
    JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
    Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
    N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.